Фармакологические свойства, экспериментальные исследования и клиническое применение тафлупроста
Аннотация
В обзоре представлена информация о тафлупросте -первом коммерчески доступном аналоге простагландина без консерванта в форме юнит-дозы. Описана фармакодинамика препарата, дана характеристика экспериментальных доклинических исследований, а также первых трех фаз клинических испытаний препарата. Показан высокий гипотензивный эффект тафлупроста при местном применении у пациентов с офтальмогипертензией и первичной открытоугольной глаукомой. Проведен анализ пострегистрационных исследований сравнительной эффективности и переносимости. Дана оценка перспектив применения нового препарата.
Список литературы
1. Brasnu E., Brignole-Baudouin F., Riancho L. [et al.] In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line // Current Eye Research. 2008. Vol. 33, No. 4. P. 303-312.
2. Burstein N.L. Preservative alteration of corneal permeability in humans and rabbits // IOVS. 1984. Vol. 25, No. 12. P. 1453-1457.
3. Egorov E., Ropo A. Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma // European Journal of Ophthalmology. 2009. Vol. 19, No. 2. P. 214-222.
4. Erb C., Lanzl I., Seidova S.F., Kimmich F. Preservative-free tafluprost 0.0015 % in the treatment of patients with glaucoma and ocular hypertension // Advances in Therapy. 2011. Vol. 28, No. 7. P. 575-585.
5. Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost // Clinical Ophthalmology. 2011. Vol. 5. P. 623-631.
6. Kashiwagi K., Tsukamoto K., Suzuki M., Tsukahara S. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes // Journal of Glaucoma. 2002. Vol. 11, No. 1. P. 57-64.
7. Kurashima H., Asai Y., Aihara M. [et al.] Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys // Journal of Glaucoma. 2012. Vol. 21, No. 2. P. 123-128.
8. Madhu C., Rix P., Nguyen T. [et al.] Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro // J. Ocul. Pharmacol. Ther. 1998. Vol. 14, No. 5. P. 389-399.
9. Mishima H.K., Masuda K., Kitazawa Y. [et al.] A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study // Archives of Ophthalmology. 1996. Vol. 114, No. 8. P. 929-932.
10. Nakajima T., Matsugi T., Goto W. [et al.] New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents // Biological & Pharmaceutical Bulletin. 2003. Vol. 26, No. 12. P. 1691-1695.
11. Ota T., Murata H., Sugimoto E. [et al.] Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation // IOVS. 2005. Vol. 46, No. 6. P. 2006-2011.
12. Pellinen P., Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost // Ophthalmic Research. 2009. Vol. 41, No. 2. P. 118-122.
13. Sutton A., Gouws P., Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers // Int. J. Clin. Pharmacol. Therap. 2008. Vol. 46, No. 8. P. 400-406.
14. Takagi Y., Nakajima T., Shimazaki A. [et al.] Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug // Experimental eye research. 2004. Vol. 78, No. 4. P. 767-776.
15. Traverso C.E., Ropo A., Papadia M., Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost // J. Ocul. Pharmacol. Ther. 2010. Vol. 26, No. 1. P. 97-104.
16. Uusitalo H., Chen E., Pfeiffer N. [et al.] Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication // Acta ophthalmologica. 2010. Vol. 88, No. 3. P. 329-336.
17. Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers // Acta ophthalmologica. 2008. Vol. 242, Suppl. P. 7-13.
18. Uusitalo H., Pillunat L.E., Ropo A., Phase I.I.I.S.I. Efficacy and safety of tafluprost 0.0015 % versus latanoprost 0.005 % eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study // Acta ophthalmologica. 2010. Vol. 88, No. 1. P. 12-19.
Рецензия
Для цитирования:
Петров С.Ю., Сафонова Д.М. Фармакологические свойства, экспериментальные исследования и клиническое применение тафлупроста. Тихоокеанский медицинский журнал. 2015;(3):11-13.
For citation:
Petrov S.Yu., Safonova D.M. The pharmacological properties, experimental research and clinical application of tafluprost. Pacific Medical Journal. 2015;(3):11-13. (In Russ.)
Просмотров: 93
Послать статью по эл. почте 
